Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest dyskinesias Stories

2013-04-17 08:27:35

U.S. and European Surveyed Neurologists Agree that Better Treatment for Motor Response Complications Remains as an Unmet Need in Parkinson's Disease, According to a New Report from Decision Resources BURLINGTON, Mass., April 17, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. neurologists indicate that the most important drug attribute for a therapy targeting...

2010-12-03 06:30:00

PALO ALTO, Calif., Dec. 3, 2010 /PRNewswire/ -- Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1/2 clinical study of NP002 for the treatment of dyskinesias (muscle movement disorders) resulting from levodopa therapy for patients with...

2010-10-04 06:32:00

PALO ALTO, Calif., Oct. 4 /PRNewswire/ -- Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases, announced today the Company has achieved last patient out in two studies: a Phase 1 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease) and a Phase 1/2 clinical study...